CurrentAetnaPolicy 0755

Motor Cortex Stimulation

Clinical policy governing use of motor cortex stimulation (MCS) — describes coverage stance, indications considered experimental/investigational, and related coding; applies to Aetna members/providers.

Policy Summary

PayerAetna

PolicyMotor Cortex Stimulation

Policy CodePolicy 0755

Change TypeNo material change

Effective DateMay 9, 2008

Next Review DateAug 8, 2024

Key ActionObtain prior authorization and document prior conservative treatments and results of any trial stimulation before seeking coverage for implantation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

14+experimental indications

0755policy id

72.6%iMCS responder rate

45.3%noninvasive responder rate

Coverage Determinations for Motor Cortex Stimulation

Experimental and investigational indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not medically necessary / experimental and investigational for the following indications:

List of indications considered experimental/investigational: Motor cortex stimulation is considered experimental and investigational for: amyotrophic lateral sclerosis; autism spectrum disorder; cerebral palsy; chronic refractory pain (including central pain syndromes, complex regional pain syndrome, neuropathic orofacial pain syndromes, peripheral neuropathic pain, phantom limb pain, thalamic pain, and trigeminal neuropathic pain); dysphagia; dystonia secondary to a focal basal ganglia lesion; movement disorders; muscle re-innervation; nerve regeneration; obsessive compulsive disorder; Parkinson's disease; post-stroke aphasia; post-stroke hemiparesis; traumatic brain injury.

Exact list as enumerated in policy.

MCS use during deep brain stimulator implantation

Use during DBS implantation: The use of motor cortex stimulation during implantation of a deep brain stimulator is considered experimental and investigational.

Explicitly listed in policy.

Efficacy evidence overview

Summary of efficacy findings and contexts where MCS has been studied

Evidence summary: Studies show mixed results: observational and meta-analytic data report responder rates for invasive MCS (weighted responder rate ~72.6%) and non-invasive (~45.3%); some randomized and crossover trials show modest or transient benefits and some failed to show significant improvement; long-term durability is variable with some patients losing effect and undergoing explantation.

Supported by meta-analysis, RCTs, crossover and observational series

Condition-specific evidence

Findings by condition and study type

Trigeminal and facial neuropathic pain: Series report favorable long-term success in facial pain (mean long-term success up to ~80% in some reports) and MCS is considered potentially useful in trigeminal neuropathic pain; classical trigeminal neuralgia may respond less well in some studies.

References: Rasche et al; Cioni and Meglio; Cheshire

Peripheral neuropathic pain: Small randomized cross-over and open-label studies suggest possible benefit in refractory peripheral neuropathic pain with mean VAS improvements (e.g., ~48% pain relief at 1 year in one series), though effects may fade over time and authors call for larger trials.

References: cross-over trial and Lefaucheur/Slotty observations

Post-stroke and central pain (PSP): Guideline summaries and pooled analyses indicate possible usefulness in central post-stroke pain and central/peripheral facial neuropathic pain in roughly 50–60% of patients (level C evidence), but overall evidence is limited and further RCTs are needed.

Reference: EFNS / Cruccu et al and guideline summaries

Other neurologic indications (PD, dystonia, ALS, OCD): MCS and noninvasive motor cortex stimulation have been explored for movement disorders, dystonia, ALS, and OCD with preliminary or mixed results; controlled definitive evidence is lacking and some trials showed no significant benefit (e.g., negative or inconclusive RCTs in dystonia/other disorders).

References: Cioni; RCTs and reviews noting insufficient evidence

Evidence-informed coverage considerations

Evidence summaries and applicability considerations from the document:

MCS evidence summary: MCS (invasive and noninvasive) demonstrates variable benefit across conditions; pooled analyses report modest to moderate pain improvement in some neuropathic pain syndromes, with better responses in certain etiologies (e.g., trigeminal neuralgia, central orofacial pain). Noninvasive methods (rTMS, tDCS) have shown short-term pain reduction for phantom limb pain. However, the literature is limited by small sample sizes, heterogeneity in diagnoses and outcome measures, methodological weaknesses, and inconsistent durability of response. These limitations support cautious, indication-specific coverage decisions and consideration of MCS as a last-resort invasive option when evidence and patient selection criteria are met.

Supports cautious application and need for better-designed trials.

Motor cortex stimulation (MCS) is designated experimental and investigational for the enumerated indications because its effectiveness has not been established. The policy lists multiple specific conditions for which MCS is considered investigational, including amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, chronic refractory pain (e.g., central pain syndromes, CRPS, neuropathic orofacial pain, peripheral neuropathic pain, phantom limb pain, thalamic pain, trigeminal neuropathic pain), dysphagia, dystonia secondary to a focal basal ganglia lesion, movement disorders, muscle re-innervation, nerve regeneration, obsessive compulsive disorder, Parkinson’s disease, post‑stroke aphasia, post‑stroke hemiparesis, and traumatic brain injury.

Procedures or indications for which the available evidence is insufficient — for example, use of MCS during implantation of a deep brain stimulator — are considered investigational and may be excluded from coverage absent enrollment in a clinical trial or compelling supporting data. Guidelines cited in the literature emphasize the need for randomized controlled trials to determine effectiveness before routine coverage is appropriate.

The literature on MCS has notable limitations that affect interpretation of results and coverage decisions: many studies have small sample sizes, lack randomized controlled designs or appropriate control groups, use heterogeneous diagnostic criteria and stimulation parameters, and often do not include standardized outcome or quality‑of‑life measures. These methodological shortcomings raise concern for bias (including potential placebo effects) and limit confidence in reported benefits.

Invasive approaches such as invasive MCS and deep brain stimulation are generally considered last‑therapeutic options for conditions like phantom limb pain. Systematic reviews note that evidence supporting invasive interventions for phantom limb pain is limited and controversial, and recommend prioritizing noninvasive modalities when evidence supports benefit.

The provided excerpt does not list additional explicit coverage exclusions beyond the investigational designations above. Aetna disclaims responsibility for content on external websites linked from the policy page.

Consistent with the policy’s experimental/investigational stance, motor cortex stimulation for the enumerated conditions is considered not medically necessary because effectiveness has not been established in the published evidence.

A small double‑blind, cross‑over pilot RCT of bipolar epidural MCS in dystonia secondary to a focal basal ganglia lesion (n = 5) did not demonstrate statistically significant improvement in dystonia, spasticity, pain, or quality of life; similarly, retrospective series of neuropathic pain have reported transient benefits with decline over time. These data support the conclusion that bipolar epidural MCS for dystonia secondary to a focal basal ganglia lesion failed to improve outcomes in the small RCT.

Multiple reviews and systematic analyses describe invasive approaches for phantom limb pain and other neuropathic pain syndromes as controversial or appropriate only as last‑resort therapies because of limited randomized controlled trial evidence, small subject numbers, and mixed trial quality; as a result, invasive MCS is not routinely supported for these indications.

Procedure, Device, and Diagnosis Codes

Procedure and mapping CPT codesCPT

61850	Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical.
61860	Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical.
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to two or more electrode arrays.
64568	Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
95961	Functional cortical and subcortical mapping by stimulation and/or recording; initial hour of physician attendance.
95962	Each additional hour of physician attendance.
95970	Electronic analysis of implanted neurostimulator pulse generator system without reprogramming.
61781	Stereotactic computer-assisted (navigational) procedure; cranial, intradural.
61782	Stereotactic computer-assisted (navigational) procedure; cranial, extradural.

1–10 of 11

1/2

Additional procedure, imaging, and neurophysiology codesmixed

61864	Each additional array (List separately in addition to primary procedure).
61867	Stereotactic implantation with intraoperative microelectrode recording; first array.
61868	Each additional array with intraoperative microelectrode recording.
61880	Revision or removal of intracranial neurostimulator electrodes.
61888	Revision or removal of cranial neurostimulator pulse generator or receiver.
70551-70553	Magnetic resonance imaging, brain (including brain stem).
70554-70555	Magnetic resonance imaging, brain, functional MRI.
95927	Short-latency somatosensory evoked potential study; recording from CNS in trunk or head.
95965-95967	Magnetoencephalography (MEG), recording and analysis.
96020	Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping.

HCPCS device codesHCPCS

C1767	Generator, neurostimulator (implantable), nonrechargeable.
C1778	Lead, neurostimulator (implantable).
C1787	Patient programmer, neurostimulator.
C1816	Receiver and/or transmitter, neurostimulator (implantable).
C1820	Generator, neurostimulator (implantable), non high-frequency with rechargeable battery and charging system.
C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable).
C1897	Lead, neurostimulator test kit (implantable).
E0745	Neuromuscular stimulator, electronic shock unit.
L8680	Implantable neurostimulator electrode, each.
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator.

1–10 of 18

1/2

ICD-10 codes mentioned in 'not covered' listsICD-10Not Covered

F42.2-F42.9	Obsessive-compulsive disorder.
F84.0	Autistic disorder.
G12.21	Amyotrophic lateral sclerosis.
G20, G21.0-G21.9	Parkinson's disease and secondary parkinsonism.
G80.0-G80.9	Cerebral palsy.
G89.0, G89.21-G89.29, G89.3, G89.4	Central pain syndrome and chronic pain diagnoses.
G50.0, G50.1	Trigeminal neuralgia; atypical facial pain.
G54.6-G54.7	Phantom limb syndrome.
I69.051-I69.959	Hemiplegia and hemiparesis, sequelae of cerebrovascular disease.
I69.320	Aphasia following cerebral infarction.

1–10 of 13

1/2

Pain reduction threshold for successful trial

Pain reduction thresholdSuccessful trial defined as greater than 50% reduction in pain on the visual analog scale (VAS)

Assessment methodPain reduction assessed using the visual analog scale (VAS)

Use in decision-makingPermanent neurostimulator implantation typically performed after a successful test stimulation showing >50% VAS reduction

Prior Authorization, Documentation, and Step Therapy Guidance

Prior Authorization

Prior Authorization: Trial Stimulation and Documentation

Prior authorization: Trial stimulation and documentation — Prior authorization should confirm that patients considered for motor cortex stimulation (MCS) have chronic neuropathic pain refractory to conservative management and that an adequate trial stimulation (when feasible) was performed and documented. Documentation should include details of the trial method (e.g., externalized epidural lead or double‑blind on/off testing), duration of trial (minimums described in source where applicable), objective and patient‑reported pain measurements (e.g., VAS), and the trial outcome (responder vs non‑responder, percent pain reduction).

Confirm diagnosis of chronic neuropathic pain and refractory status to conservative therapies
Document adequate trial stimulation method, duration, and quantitative pain outcomes (e.g., VAS, MQS)
If trial stimulation identifies non‑responders on double‑blind testing, document and do not proceed to permanent implantation

Prior Authorization

Prior Authorization: Document Prior Therapies and Patient Selection

Prior authorization should document prior therapies and selection — Prior authorization requests must document prior conservative and interventional therapies attempted (pharmacologic trials such as amitriptyline or sodium channel blockers, intrathecal therapies when used, physical therapy, noninvasive neuromodulation) and the clinical rationale for progression to invasive MCS. Include objective assessments of prior therapy response and any contraindications or intolerance to less invasive options.

List prior pharmacologic therapies and outcomes (including dose/duration)
Document prior noninvasive neuromodulation (rTMS, tDCS) trials and results where applicable
Provide rationale for selecting MCS versus other invasive options (e.g., thalamic stimulation, DBS)

Denial Risk

Denial Risk: Experimental / Investigational Indications

Denial risk for experimental/investigational indications — Coverage denials may be issued when MCS is proposed for indications listed in the policy as experimental and investigational (e.g., amyotrophic lateral sclerosis, autism spectrum disorder, dystonia secondary to focal basal ganglia lesion, movement disorders, many listed chronic pain subtypes). The policy lists specific conditions considered experimental/investigational due to insufficient evidence.

Refer to the policy's experimental/investigational indication list when assessing requests
Requests for indications designated experimental/investigational are subject to denial

Denial Risk

Evidence Quality Risk for Coverage

Evidence quality risk for coverage — The evidence base for MCS is limited: small sample sizes, lack of adequate control groups in many studies, variable stimulation parameters, and heterogeneity of patient selection. These limitations increase the risk that requests will not meet medical‑necessity thresholds.

Lack of well‑designed RCTs and small uncontrolled studies noted in the literature
Variability in electrode placement and stimulation parameters reduces generalizability
Guidelines call for additional RCTs; absence of high‑quality evidence may justify noncoverage or further documentation requests

Note

Not Applicable / Missing Operational Details

Not applicable content in this document — This policy excerpt does not provide a comprehensive list of prior authorization codes or an explicit step‑therapy enforcement algorithm. Where explicit operational requirements are absent, follow payer‑specific prior authorization processes and coding guidance.

No exhaustive prior authorization CPT/HCPCS code list provided in this excerpt
No explicit step‑therapy sequencing mandated in this excerpt

Note

Site Disclaimer and External Links

Site disclaimer and external links — The policy includes standard Aetna site disclaimers and links to external resources for informational use only. External links do not establish coverage, authorization requirements, or clinical guidance.

External links (glossary, FAQs, legal notices) are for convenience only
Aetna is not responsible for content on non‑Aetna sites; following a link does not alter coverage determinations

Documentation Required

Required Clinical Documentation

Documentation of prior therapies and trial stimulation — Providers should supply complete clinical records with prior authorization requests: prior treatment history, failed conservative measures, details of any trial stimulation (method, duration, objective outcomes), imaging and intraoperative mapping if performed, and planned implantation approach.

Objective outcome measures (VAS, MQS, QOL indices) pre‑ and post‑trial stimulation
Imaging reports (MRI/fMRI) and intraoperative neurophysiological monitoring details where available
Operative notes describing electrode placement and stimulation parameters

Documentation Required

Supporting Clinical Documentation

Supporting clinical documentation — When available, include advanced imaging, functional mapping, standardized outcome or quality‑of‑life measures, and technical details (electrode array, stimulation parameters). These supporting data can help assess appropriateness and selection.

Imaging (70551–70555, functional MRI) and neurofunctional testing results
Neurophysiologic mapping or monitoring reports (e.g., 95961/95962)
Standardized outcome measures (VAS, McGill, MQS, QLI) and long‑term follow‑up data

Note

Operational Limits: No Concrete Automatic Triggers in Excerpt

This excerpt does not provide concrete denials or procedural triggers — While the policy identifies experimental/investigational indications and summarizes evidence gaps, it does not enumerate specific automatic denial triggers beyond designation of experimental indications. Operational prior authorization and denial decisions should be based on full policy, clinical evidence, and payer coding rules.

No automatic procedural denial list beyond experimental/investigational indications in excerpt
Use full policy and payer rules for final authorization/denial decisions

Step Therapy

Step Therapy / Sequencing Guidance

Step therapy / sequencing — The clinical background indicates MCS is a last‑resort invasive electrostimulation option after trials of first‑line pharmacologic therapies and less invasive neuromodulation. Prior authorization should confirm that less invasive and guideline‑recommended therapies were attempted and documented.

First‑line pharmacologic agents (e.g., amitriptyline, sodium channel blockers) should be tried where indicated
Consider intrathecal options and noninvasive neuromodulation (rTMS, tDCS) prior to invasive MCS when appropriate
Document reasons for bypassing standard stepwise therapies (intolerance, contraindication, or documented failure)

Step Therapy

Trial of Noninvasive Therapies Before Invasive MCS

Trial of noninvasive therapies before invasive MCS — Evidence summarized in the policy supports consideration of noninvasive neuromodulation (rTMS, tDCS) as beneficial in some conditions (e.g., phantom limb pain). Prior authorization should document trials and outcomes of these noninvasive modalities when clinically appropriate.

Document trials of rTMS or tDCS with parameters and outcomes when performed
If noninvasive neuromodulation was not feasible or contraindicated, include rationale in the request

Note

Absence of Mandated Step Therapy in This Excerpt

No step therapy requirements described / No step therapy requirements mentioned — The policy excerpt does not state formal, prescriptive step‑therapy requirements or a mandated sequence of prior authorizations; it emphasizes that invasive MCS is generally reserved after failure of less invasive measures.

No explicit mandatory step‑therapy protocol specified in excerpt
Clinical judgment and individualized documentation drive sequencing decisions

Background and Evidence Summary

Motor cortex stimulation encompasses both surgically implanted (epidural or subdural electrode) systems and noninvasive techniques (e.g., rTMS, tDCS). It has been used as a staged procedure with temporary trial stimulation prior to permanent implantation and has primarily been studied in refractory chronic neuropathic pain conditions. The clinical evidence is limited and largely derived from small uncontrolled series, meta‑analyses, and some randomized or crossover trials that report variable and sometimes transient benefit.

Efficacy evidence overview

Summary of efficacy findings and contexts where MCS has been studied

Evidence summary (background): Systematic reviews and meta-analyses of invasive and noninvasive motor cortex stimulation report higher responder rates for invasive approaches (weighted responder rate ~72.6%) compared with noninvasive (~45.3%), but highlight the need for well-designed sham-controlled trials and further research on duration of effect and stimulation parameters.

Cites Lima & Fregni meta-analysis and long-term series

Condition-specific evidence

Condition-specific evidence summarized for background context

Trigeminal, peripheral, central pain summaries: Retrospective series, cross-over trials and pooled analyses report variable outcomes by condition: facial (trigeminal) pain often shows higher success rates (reports up to ~80% long-term), peripheral neuropathic pain shows moderate mean VAS relief (~48% in one series) but durability is inconsistent, and pooled analyses show 35.2% improvement in post-stroke pain and 46.5% in trigeminal neuropathic pain in some reviews.

Supports nuanced interpretation by etiology

As noted elsewhere in the policy background, the MCS literature is constrained by small samples, lack of rigorous RCTs, heterogeneous diagnostic and outcome measures, variable stimulation parameters, and potential placebo effects. These recurring limitations are highlighted in multiple evidence reviews and inform the policy’s investigational and not‑medically‑necessary determinations.

Key Terms and Definitions

Motor cortex stimulation (MCS) — definition

DefinitionImplantation of one or more electrodes extra-durally over the primary motor cortex connected to an implantable, battery-powered neurostimulator to deliver electrical stimulation

Typical procedureUsually performed in two operations: (1) electrode placement guided by computer-aided neuro-navigation and MRI; (2) implantation of the neurostimulator after successful test stimulation

Device placementNeurostimulator is placed subcutaneously near the clavicle and connected to the cortical electrode(s)

Trial stimulation — definition and role

DefinitionA temporary stimulation period (test stimulation) to assess pain reduction prior to permanent implantation of the neurostimulator

Success criterion exampleMany series define a successful trial as >50% pain reduction on VAS leading to permanent implantation

Role in workflowTrial stimulation guides decision to proceed with permanent neurostimulator implantation

Central pain syndrome — definition and examples

DefinitionA neurological condition caused by damage to or dysfunction of the central nervous system (brain, brainstem, spinal cord)

Common causes/examplesCan be caused by stroke, multiple sclerosis, tumors, epilepsy, brain or spinal cord trauma, or Parkinson disease

Clinical relevanceCentral pain syndrome is among indications studied for MCS in chronic refractory pain

Noninvasive motor cortex stimulation — definitions and examples

DefinitionNeuromodulation techniques that stimulate the motor cortex without surgery, e.g., repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS)

Examples of indications studiedStudied for phantom limb pain (PLP), obsessive-compulsive disorder (OCD), and other refractory pain syndromes

Role relative to invasive MCSNoninvasive methods are often considered before invasive MCS and have shown short-term benefit in some conditions

Invasive motor cortex stimulation (iMCS) — definition

DefinitionSurgically implanted epidural or subdural electrodes placed over the motor cortex and connected to an implanted pulse generator (neurostimulator)

Typical indicationStudied for refractory chronic neuropathic orofacial pain and other intractable pain syndromes as a last-resort option

Procedure notesElectrodes placed via burr hole or small craniotomy and connected to a subcutaneous pulse generator; often staged with a trial stimulation

tDCS — transcranial direct current stimulation

DefinitionTranscranial direct current stimulation (tDCS) — a noninvasive technique applying low-intensity direct current (e.g., anodal M1 tDCS) over the motor cortex to modulate cortical excitability

Example protocolBolognini et al (2015): anodal tDCS applied for 15 minutes at 1.5 mA for 5 consecutive days produced sustained short-term PLP relief

Clinical effectMeta-analytic evidence indicates anodal M1 tDCS can have a significant short-term effect in reducing phantom limb pain

rTMS — repetitive transcranial magnetic stimulation

DefinitionRepetitive transcranial magnetic stimulation (rTMS) — a noninvasive neuromodulation method using repeated magnetic pulses (e.g., 10-Hz over M1) to modulate neuronal plasticity

Example protocolOpen-label study of 10-Hz rTMS over M1 for 10 consecutive days (1,000 pulses/day) showed decreased VAS scores lasting up to 8 weeks in thalamic pain

Clinical usesStudied for thalamic pain, phantom limb pain, and neuropsychiatric indications such as OCD (low-frequency rTMS to supplementary motor area)

MCS — umbrella definition

DefinitionMotor cortex stimulation (MCS) — umbrella term encompassing both invasive cortical stimulation (epidural/subdural electrodes with implanted pulse generator) and noninvasive brain stimulation techniques (rTMS, tDCS) targeting the motor cortex

ScopeIncludes surgically implanted iMCS and noninvasive neuromodulation methods used to modulate motor cortex activity for pain and other neurologic conditions

Clinical positioningMCS approaches are often considered last-resort invasive options; noninvasive MCS may be trialed first when evidence supports benefit

Policy Revision Timeline

2008-05-09effective_date

Policy became effective.

2023-10-06last_reviewLatest

Policy last reviewed; review date recorded in policy history.

Policy Summary

PayerAetna

PolicyMotor Cortex Stimulation

Policy CodePolicy 0755

Change TypeNo material change

Effective DateMay 9, 2008

Next Review DateAug 8, 2024

Key ActionObtain prior authorization and document prior conservative treatments and results of any trial stimulation before seeking coverage for implantation.

SourceLink

On This Page